Network-based methods are playing an increasingly important role in drug design. Our main question in this paper was whether the efficiency of drug target proteins to spread perturbations in the human interactome is larger if the binding drugs have side effects, as compared to those which have no reported side effects. Our results showed that in general, drug targets were better spreaders of perturbations than non-target proteins, and in particular, targets of drugs with side effects were also better spreaders of perturbations than targets of drugs having no reported side effects in human protein-protein interaction networks. Colorectal cancer-related proteins were good spreaders and had a high centrality, while type 2 diabetes-related proteins showed an average spreading efficiency and had an average centrality in the human interactome. Moreover, the interactome-distance between drug targets and disease-related proteins was higher in diabetes than in colorectal cancer. Our results may help a better understanding of the network position and dynamics of drug targets and disease-related proteins, and may contribute to develop additional, network-based tests to increase the potential safety of drug candidates.
Introduction
Due to the "curse of attrition" drug side effects are subjects of increasing concerns [1] [2] [3] [4] . In recent years a growing number of side effect databases helped pharmacovigilance efforts 2, [5] [6] [7] [8] [9] [10] . In addition, the prediction of drug side effects was a subject of several excellent network studies. These contributions constructed and analyzed drug-side effect networks 1, 8, 11 , side effect similarity-based drug-drug networks [12] [13] [14] , drug target-side effect networks (including correlated drug binding profiles and side effect profiles and protein domain networks) 3, 5, 7, 15, 16 , as well as drug-side effect-biological pathway multi-layer networks 9, 10, 17, 18 . Parallel with the sequencing of the human genome, the pharmaceutical industry increasingly turned towards rational drug design, where drug target candidates are selected on the basis of known disease-related genes. In recent years, however, it became apparent that drug action often extends beyond its primary target, and also affects the neighbourhood of the primary target in molecular networks 4, [19] [20] [21] [22] [23] . The influence on network neighbourhood can be efficiently modelled as a spreading process. Indeed, network spreading efficiency became increasingly used to characterize the dynamics of a wide variety of networks, such as the propagation of infections and computer viruses [24] [25] [26] , as well as the spread of information, innovations and social influence [27] [28] [29] [30] . Long-range spread of conformational changes via protein-protein interaction networks is supported by several pieces of experimental evidence 31, 32 . Moreover, recent studies extended the use of information-spread to molecular networks highlighting the usefulness of this approach in finding key amino acids of protein structure networks, biologically relevant changes of cellular functions upon stress, reprogramming biological networks, and uncovering the attractor changes in malignant transformation [33] [34] [35] [36] . However, network spreading efficiency has been used to characterize drug targets neither in general, nor restricted to targets of drugs having side effects.
In this study we investigated, whether the efficiency of drug target proteins to spread perturbations in the human interactome is larger, if drugs targeting them have side effects, as compared to the spreading efficiency of targets of those drugs, which have no reported side effects. Encouraged by our findings that drug targets in general, and targets of drugs having side effects in particular, spread perturbation better in the human interactome than other proteins, we specifically examined two diseases, colorectal cancer and diabetes. These two, wide-spread diseases were selected, since they represent target groups of different drug design strategies 4 , and they had been the subjects of several former network-related studies [37] [38] [39] [40] [41] [42] [43] [44] [45] . We found that colorectal cancer-related proteins were good spreaders and had a high centrality in the human protein-protein interaction network. On the contrary, type 2 diabetes-related proteins showed an average spreading efficiency, and had an average centrality. Additionally, network shortest path (geodesic distance) between drug targets and disease-related proteins was higher in diabetes than in colorectal cancer. Our results give novel details on the network topology and dynamics of disease-related and drug target proteins, and may initiate the development of novel, networkbased pharmacovigilance methods increasing the potential safety of drug candidates.
Results

Targets of drugs with side effects spread perturbations better in the human interactome than targets of drugs without side effects
The initial working hypothesis of our research was that drugs having protein targets that better propagate changes in the human interactome may have a higher probability of causing side effects. This hypothesis is in agreement with earlier findings showing that the interactome neighbourhood contributed to drug side-effect similarity 20 . In order to test our hypothesis, we compared the propagation of perturbations started from drug targets with and without known side effect, as well as that of non-target proteins in the human protein-protein interaction network using the Turbine network dynamics software package developed earlier in our group 35 . To compare the spreading efficiency of drug target proteins with and without side effects we ran a series of perturbation simulations on the human interactome using the Turbine programme 35 . We assembled a human interactome containing 12,439 proteins and 174,666 edges using the STRING database 46 , out of which 1,726 were target proteins of 3,626 human drugs obtained from the DrugBank database 47 and a total of 99,423 drug-side effect pairs from the SIDER database 2 were analysed as described in Methods in detail. Simulations were based on the communicating vessels network dynamics model tested earlier 35 , where changes from one protein to its neighbours 'flow' in proportion with the energy differences between the 'source' and the 'target' proteins. We examined a total of 495 target proteins of 597 drugs (Suppl. Table 1 ), which were reported to have side effects according to the SIDER database 2 . As control groups, we have also examined the 1,231 target proteins of the remaining 3,029 drugs having no reported side effects in the SIDER database 2 , as well as the remaining 10,713 proteins in our human interactome, which were not listed as drug targets in DrugBank 47 . For each selected protein target we calculated the silencing time, which is the number of time steps in the simulation needed for the initial perturbation to disappear completely due to dissipation. Small silencing time values were shown to be an efficient measure of large spreading efficiency of network nodes earlier 35 , since in this case the initial perturbation efficiently spreads in the network and it becomes dissipated fast. Fig. 1 shows the cumulative distribution of the normalized number of proteins having an increasing silencing time (thus decreasing perturbation efficiency). Targets of drugs with side effects had a significantly larger proportion of small silencing times (i.e. large spreading efficiency) than targets of drugs having no side effects (Mann-Whitney-Wilcoxon test, p=1.677e-5). Similarly, the proportion of targets of drugs without side effects having a small silencing time (i.e. large spreading efficiency) was significantly larger than that of human interactome proteins, which have not been reported as drug targets in DrugBank 47 (MannWhitney-Wilcoxon test, p=2.2e-16). Thus targets of drugs with side effects were found to be better spreaders of perturbations than targets of drugs having no reported side effects. Importantly, drug targets were also better spreaders of perturbations than non-target proteins.
Simulations shown on Fig. 1 were run with a starting energy of 1,000 units and a dissipation value of 5 units. Being curious whether our result is robust for the variations of simulation parameters, we repeated these simulations using a starting energy of 10,000 and a dissipation of 1 or 5 units. Under these conditions we obtained very similar results (Suppl. Figs. 1 and 2) to those shown on Fig. 1 . When we split the starting energy of 1,000 units equally among targets of multi-target drugs instead of examining each target protein alone as the source of perturbations, we were able to reproduce the same pattern (Suppl. Fig. 3) as that of Fig. 1 . Furthermore, to test the robustness of the results against the choice of protein-protein interaction network, we randomly deleted 50% of the 12,439 proteins in our human interactome. Examining the spreading efficiency in the giant component of this truncated interactome we obtained very similar results (Suppl. Fig. 4 ) to those shown in Fig. 1 .
Next we were curious whether the larger spreading efficiency of drug targets with side effects, as compared to drug targets without side effects or proteins having no reported drugs bound to them, is also shown by examining perturbation reach values. Perturbation reach values show the number of proteins, which received the perturbation from the initial perturbation source protein until the perturbation was dissipated from the system. Small perturbation reach values were shown to characterize small spreading efficiency in earlier studies 35 , since in this case the original perturbation reached only a small number of proteins before it became dissipated. Targets of drugs with side effects had a significantly smaller proportion of small perturbation reach values (i.e. small spreading efficiency) than that of targets of drugs having no side effects (Mann-Whitney-Wilcoxon test, p=1.663e-5; Suppl. Fig. 5) . Similarly, the proportion of targets of drugs without side effects having a small perturbation reach value (i.e. small spreading efficiency) was significantly smaller than that of human interactome proteins, which have not been reported as drug targets in DrugBank 47 (Mann-Whitney-Wilcoxon test, p=2.2e-16; Suppl. Fig. 5 ). Using a starting energy of 10,000 but a dissipation of 1 instead of 5 units, or splitting this starting energy equally among targets of multi-target drugs, we obtained very similar results (Suppl. Figs. 6 and 7). These studies confirmed that drug targets are better spreaders of perturbations than non-target proteins, and also that targets of drugs with side effects are better spreaders of perturbations than targets of drugs having no reported side effects.
A qualitatively similar picture emerged, when we examined the spreading efficiency of target proteins of drugs against two diseases, colorectal cancer and type 2 diabetes (Suppl. Tables 2-6). We chose these two diseases, because they represent very well the target groups of different drug design strategies 4 , and they had been the subjects of several former network-related studies [37] [38] [39] [40] [41] [42] [43] [44] [45] . Drug targets of both diseases were found to be better spreaders of perturbations than non-target proteins (Suppl. Fig. 8 ; p=3.367e-5 and p=5.88e-5 for colorectal cancer and diabetes, respectively). There was a tendency showing that targets of drugs with side effects were better spreaders of perturbations than targets of drugs having no reported side effects both in colorectal cancer and in diabetes. However, due to the low number of identified drug targets having side effects (3 and 25, respectively), these latter differences were not statistically significant (p=1 and p=0.2593, respectively).
Colorectal cancer-related proteins are good spreaders of perturbations and have a high centrality, while type-2 diabetes-related proteins show an average spreading efficiency and average centrality Very importantly, a rather interesting difference emerged, when we examined the spreading efficiency of proteins related to colorectal cancer and diabetes. Mutated genes and their corresponding proteins in colorectal cancer and in type-2 diabetes were obtained from the Cancer Gene Census database 48 (Suppl. Table 7 ) and from the article of Parchwani et al. 49 (Suppl . Table  8) , respectively. In case of colorectal cancer, disease-associated proteins were found to be significantly better spreaders than the residual proteins of the human interactome. On the contrary, diabetes-related proteins showed indistinguishable spreading properties to the rest of human proteins, which were not associated with the onset of diabetes (Fig. 2) . To test the robustness of the results against the choice of protein-protein interaction network, we randomly deleted 50% of the 12,439 proteins in our human interactome. Here again, colorectal cancerassociated proteins were found to be significantly better spreaders than the residual proteins of the human interactome (data not shown; p=0.00021 in Mann-Whitney test) and spreading efficiency of diabetes-related proteins showed no significant difference as compared to the rest of human proteins (data not shown; p=0.095 in Mann-Whitney test).
These findings are in agreement with earlier results showing that cancer-associated proteins are enriched in proteins having a high centrality in the human interactome 37, 38, 40, [42] [43] [44] [45] . Indeed, in our human interactome, cancer-related proteins had a significantly higher degree, closeness and betweenness centralities than diabetes-related proteins, having a 9.6-, 1.2-and 54-fold increase, respectively (Table 1 ). In agreement with their similar silencing time values (Suppl. Fig. 8 ), drug targets without or with side effects showed no significant centrality differences in the human interactome (Suppl. Table 9 ).
The interactome distance between drug targets and disease-related proteins is higher in diabetes than in colorectal cancer Encouraged by the results showing an increased centrality of cancer-related, but not of diabetesrelated proteins in the human interactome, we examined the interactome geodesic distance (i.e. shortest path) between drug targets and disease related proteins in both diseases using the neighbourhood matrices of related proteins. Our data show that the geodesic distance in the human interactome between drug targets and disease-related proteins is significantly larger in case of type-2 diabetes than in colorectal cancer (targets without side effects: p=1.062e-5; targets with side effects: p=5.441e-3). (Table 2; Suppl. Tables 10-13 and Suppl. Fig. 9 ) This finding is supported by the visual representation of the human sub-interactome of drug target and diseaserelated proteins of these two diseases (Suppl. Fig. 10 ), where drug targets and disease-related proteins of colorectal cancer are intertwined, while these two groups of proteins remain rather separated in type-2 diabetes. This observation is further substantiated by the fact, that only 1 of the 18 colorectal cancer-related proteins (6%) is not connected to the giant component of the subinteractome, while 10 of the 14 diabetes-related proteins (71%) are missing from the same giant component (Suppl. Fig. 10 ).
Discussion
The most important finding of our study is that 1.) drug targets are better spreaders of perturbations in the human interactome than non-target proteins in general; and in particular, 2.) targets of drugs with side effects are also better spreaders of perturbations than targets of drugs having no reported side effects (Fig. 1) . These findings were robust, since they could be reproduced when we used different perturbation parameters (Suppl. Figs. 1, 2 and 3 ), different measures of perturbation spread (Suppl. Figs. 5, 6 and 7), and reduced the size (coverage) of the human interactome to half of the original (Suppl . Fig. 4 ). These results are in agreement with those of a previous study showing that the interactome neighbourhood contributed to side-effect similarity 20 . Importantly, colorectal cancer-related proteins are good spreaders of perturbations and had a high centrality, while type-2 diabetes-related proteins showed an average spreading efficiency and had an average centrality in the human interactome ( Fig. 2 and Table 1 ). These findings are in agreement with earlier results showing that cancer-associated proteins are enriched in hubs, bottlenecks and bridges all having a high centrality in the human interactome 37,38,40,42-45 . Furthermore, the interactome-distance between drug targets and disease-related proteins was higher in diabetes than in colorectal cancer ( Table 2 ; Suppl. Tables 10-13 and Suppl. Fig. 9 ). This finding is in agreement with both the results of previous studies and intuitive insights on the classification of drug target strategies 4 . Most drug targets are 3 or 4 steps away in the human interactome from proteins involved in the same disease 50 . Moreover, cancer-related and metabolic disease-related proteins were shown to have an average network distance to the related drug targets of 2.3 and ~5 network edges, which are smaller and higher than the most abundant distance values, respectively, forming the two extremes of the distance-spectrum 50 . The former value is in the range we found in our study ( Table 2 ). The latter value of a disease group containing diabetes is much larger than that related to cancer, which is again in agreement with our findings. As a general trend, rapidly proliferating cells, like those in cancer, are attacked at their central proteins, while differentiated cells, such as those involved in type-2 diabetes, are attacked at the neighbours of central proteins 4 . These assumptions are also in agreement with a smaller network distance of centrally positioned cancer-related proteins from centrally positioned cancer drug targets than the distance between the more peripheral diabetes-related proteins and drug targets.
Analysis of perturbation spread in molecular networks may be used to develop additional, network-based tests to increase the potential safety of drug candidates. Assessment of perturbation spread in weighted networks (where the edges are weighted according to the abundance of their end-node proteins of relevant tissues, e.g. the endothelial cell in colorectal cancer, as well as hepatocyte and myocyte in diabetes, as described in our earlier study for the yeast interactome 51 ), directed networks (such as signalling networks 4, 52 ), or networks considering the subcellular localization of participating proteins 53 , as well as using quantitative measures of side-effect severity and abundance may provide additional information and will be subjects of later studies.
In summary, our results contributed to a better understanding of the network position and dynamics of disease-related and drug target proteins. The findings may help the future development of novel, network-based pharmacovigilance methods increasing the potential safety of drug candidates.
Methods
Construction of the human protein-protein interaction network
In this paper, we examined the propagation of perturbations in the human protein-protein interaction network (interactome). The choice of this type of network was driven by the fact that it contains the most proteins and the greatest number of connections (as opposed to signalling networks or regulatory networks). Human interactome data were downloaded from the STRING database 46 on 8 February, 2013. STRING contains interaction data based on a vast number of data collection principles. We have only used manually collected ('database' column) or experimental ('experiments' column) data having higher reliability than e.g. predicted data. Only human protein-protein interactions were included in the interactome. In order to facilitate the comparison with drug targets, the STRING Ensemble Protein ID (ENSP) protein codes were translated to UniProt ID 54 using the UniProt translator. From the original 13,484 ENSP IDs we managed to translate 12,493 to UniProt IDs, but only 12,439 proteins were connected to other proteins. The database contained a total of 377,920 human protein-protein interactions, out of which 350,528 remained after translating the protein IDs to UniProt IDs using the UniProt translator, which were further reduced to 174,666 after eliminating multiple links and loops (selflinks). The original STRING database also contained edge weights indicating the reliability of data. Since we only worked with manually collected and experimental data, our interactome contained no edge weights.
Measurement of the propagation of perturbations in the human interactome
The propagation of perturbations in the human interactome was measured with the network perturbation analysis software for simulating network dynamics called Turbine
35
. For the simulation experiments we chose the software's communicating vessels model 35 , where changes from one protein to its neighbours 'flow' in proportion with the energy differences between the 'source' and the 'target' proteins. The communicating vessels model 35 contains a starting energy (E) and a dissipation parameter (D), where the starting energy is distributed equally among the proteins of the human interactome specified at the individual simulations, while in each step of the simulation the program subtracts D units of energy from each protein of the interactome. In most simulations E and D were set to 1000 and 5 units, respectively. Having these starting energy and dissipation parameters it was possible to trace the propagation of perturbations in the network rather easily. However, all the key simulations were also examined using different E and D values to examine the robustness of the results. To characterise the propagation efficiency of the starting node(s), the measure of silencing time 35 was used, which is the time elapsed from the start of the simulation until the energy of all nodes reaches the minimum threshold of less than 1 unit. We also calculated perturbation reach values 35 , which show the number of proteins receiving the perturbation from the initial perturbation source protein until the perturbation was dissipated from the system. After comparison with the drug-side effect data from the SIDER database 2 , we found that 597 drugs (with a total of 495 target proteins) had known side effects, while the remaining 3,029 drugs (with 1,231 target proteins) had no reported side effects to date.
Characterisation of drug side effects
Protein and drug target data related to the two examined diseases: colorectal cancer and type 2 diabetes
Genes involved in colorectal cancer were collected from the Cancer Gene Census 48 database, by selecting those proteins in the entire database that contained the word 'colorectal' in their 'Tumour Types' column. Genes related to type 2 diabetes were obtained from the article of Parchwani et al.
49
. The 18 genes involved in colorectal cancer and the 46 genes related to type 2 diabetes were then mapped to proteins marked by UniProt ID 54 with the help of the Protein Identifier CrossReference (PICR) 55 application. See Suppl. Tables 7 and 8 for the genes and their respective proteins involved in the two diseases. From these proteins, all 18 colorectal cancer-related but only 14 type 2 diabetes-related were contained in our interactome. Drugs used in treatment of colorectal cancer and diabetes and their drug targets were collected based on the drug indications in the DrugBank database 47 . See Suppl. Table 2 for the relevant keywords used. We found 11 drugs against colorectal cancer and 36 against type 2 diabetes, which all had valid targets. Drugs against colorectal cancer and type 2 diabetes had 33 and 42 target proteins, respectively, out of which 27 and 39, respectively, were contained in our human interactome.
Other methods
A number of Bash shell scripts were written to automate the network simulation experiments with Turbine. Statistical analysis of the results was performed with the R software package 56 . The Pajek software 57 was used to measure geodesic distances and centralities in the human interactome, the Cytoscape software 58 was used to create images of the human interactome and the Inkscape software 59 was used to create some other images. 
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Figure 1│Cumulative silencing time distribution of drug targets and non-target proteins with a starting energy of 10,000 and a dissipation value of 5. The diagram shows the cumulative distribution of the normalized number of proteins with given silencing times, which are drug targets with known side effects (blue dashed line), which are drug targets without known side effects (red solid line) and which are not drug targets (green dotted line). The number of proteins was normalized by dividing the number of proteins in each silencing time range by the total number of proteins allowing a better comparison. The total number of drug targets with and without side effects, and non-target proteins was 495, 1,231 and 10,713, respectively. The figure shows the 99.99% of all proteins (having a silencing time below 1500). The human interactome containing 12,439 proteins and 174,666 edges was built from the STRING database 1 , 1,726 human drug targets were obtained from the DrugBank database 2 and 99,423 drug-side effect pairs were taken from the SIDER database 3 . Silencing times were calculated separately for every protein with the Turbine program 4 as described in the Methods section of the main text with a starting energy of 10,000 and a dissipation value of 5 units. Statistical analysis was performed using the Mann-Whitney (Wilcoxon rank sum) test function of the R package 5 . There was a statistically significant difference (p=1.701e-5) between the silencing times of drug targets with known side effects and the silencing times of drug targets without known side effects. The difference between the silencing times of drug targets and nontarget proteins was also statistically significant (p=2.2e-16). and 99,423 drug-side effect pairs were taken from the SIDER database 3 . Silencing times were calculated separately for every protein with the Turbine program 4 as described in the Methods section of the main text with a starting energy of 10,000 and a dissipation value of 1 unit. Statistical analysis was performed using the Mann-Whitney (Wilcoxon rank sum) test function of the R package 5 . There was a statistically significant difference (p=9.635e-6) between the silencing times of drug targets with known side effects and the silencing times of drug targets without known side effects. The difference between the silencing times of drug targets and non-target proteins was also statistically significant (p=2.2e-16). . Silencing times were calculated separately for every protein/drug with the Turbine program 4 as described in the Methods section of the main text with a starting energy of 1000 and a dissipation value of 5 units. In case of drugs with multiple targets, the starting energy was distributed evenly among the drug targets. Statistical analysis was performed using the Mann-Whitney (Wilcoxon rank sum) test function of the R package 5 . There was a statistically significant difference (p=2.2e-16) between the silencing times of drugs with known side effects and the silencing times of drugs without known side effects. The difference between the silencing times of drugs and non-target proteins was also statistically significant (p=2.2e-16).
Figure 4│Cumulative silencing time distribution of drug target proteins and non-target
proteins with a starting energy of 1000 and a dissipation value of 5 using a 50% smaller interactome. The diagram shows the cumulative distribution of the normalized number of proteins with given silencing times, which are drug targets with known side effects (blue dashed line), which are drug targets without known side effects (red solid line) and which are not drug targets (green dotted line). The number of proteins was normalized by dividing the number of proteins in each silencing time range by the total number of proteins allowing a better comparison. The total number of drug targets with and without side effects, and non-target proteins was 495, 1,231 and 10,713, respectively. The human interactome containing 12,439 proteins and 174,666 edges was built from the STRING database 1 , 1,726 human drug targets were obtained from the DrugBank database 2 and 99,423 drug-side effect pairs were taken from the SIDER database 3 . 50% of the original interactome proteins were deleted randomly. The giant component of the remaining interactome contained 5,549 proteins (45%), 806 drug target proteins total (47%) and 232 drug targets with known side effects (47%). Silencing times were calculated separately for every protein with the Turbine program 4 as described in the Methods section of the main text with a starting energy of 1,000 and a dissipation value of 5 units. Statistical analysis was performed using the Mann-Whitney (Wilcoxon rank sum) test function of the R package 5 . There was a statistically significant difference (p=3.368e-4) between the silencing times of drug targets with known side effects and the silencing times of drug targets without known side effects. The difference between the silencing times of drug targets and nontarget proteins was also statistically significant (p=2.2e-16). . The number of proteins was normalized by dividing the number of proteins in each silencing time range by the total number of proteins allowing a better comparison. The total number of drug targets used in the treatment of colorectal cancer with and without side effects was 3 and 24, respectively, while for type 2 diabetes the total number of drug targets was 25 and 14, respectively. The human interactome containing 12,439 proteins and 174,666 edges was built from the STRING database 1 , 1,726 human drug targets were obtained from the DrugBank database 2 and 99,423 drug-side effect pairs were taken from the SIDER database 3 . Silencing times were calculated separately for every protein with the Turbine program 4 as described in the Methods section of the main text with a starting energy of 1,000 and a dissipation value of 5 units. Statistical analysis was performed using the Mann-Whitney-Wilcoxon test of the R package 5 . No statistically significant difference could be shown between silencing times of targets with known side effects and silencing times of targets without known side effects of drugs used in the treatment of colorectal cancer (p=1) and type 2 diabetes (p=0.2593). However, the difference between the silencing times of drug targets and non-target proteins was statistically significant for drug targets used in the treatment of both colorectal cancer (p=3.367e-5) and type 2 diabetes (p=5.88e-5).
Figure 9│Human interactome distance between drug targets used in the treatment of colorectal cancer and type 2 diabetes, between proteins related to these diseases and randomly selected proteins. The figure shows the average human interactome distances between the following proteins: drug targets used in the treatment of colorectal cancer and type 2 diabetes with and without side effects (orange circles), proteins related to these diseases (green circles) and randomly selected proteins (blue circles). The sides of the triangles (the distance between the centres of the circles) are proportional to the average number of human interactome edges between the respective protein groups, while the vertical lines associated with the sides of the triangles correspond to the standard deviation (SD). The average distance between randomly selected proteins and disease-related proteins was 2.82 edges (SD: 0.601) for colorectal cancer and 3.43 edges (SD: 0.557) for type 2 diabetes; between randomly selected proteins and drug targets with side effects was 3.24 edges (SD: 0.551) for colorectal cancer and 3.44 edges (SD: 0.490) for type 2 diabetes; between randomly selected proteins and drug targets without side effects was 3.32 edges (SD: 0.533) for colorectal cancer and 3.41 edges (SD: 0.545) for type 2 diabetes; between disease-related proteins and drug targets with side effects was 2.39 edges (SD: 0.242) for colorectal cancer and 3.23 edges (SD: 0.522) for type 2 diabetes; between diseaserelated proteins and drug targets without side effects was 2.53 edges (SD: 0.388) for colorectal cancer and 3.25 edges (SD: 0.402) for type 2 diabetes. Sizes of the circles are proportional to the number of proteins contained in each group. There were 50 randomly selected proteins; 18 colorectal cancer-related and 14 type 2 diabetes-related proteins; 3 drug targets with and 24 drug targets without side effects used in the treatment of colorectal cancer; 25 drug targets with and 14 drug targets without side effects used in the treatment of type 2 diabetes. The human interactome containing 12,439 proteins and 174,666 edges was built from the STRING database 1 , 1,726 human drug targets were obtained from the DrugBank database 2 and 99,423 drug-side effect pairs were taken from the SIDER database 3 . Network distances were calculated as shortest paths using the Pajek programme 6 as described in the Methods section of the main text and are detailed in Tables 10-13. The figure was created using Inkscape 7 .
Figure 10│Human protein-protein interaction network of the proteins related to colorectal cancer and type 2 diabetes and the drug targets used in the treatment of these diseases. The figure shows the giant component of the human protein-protein interaction network containing the proteins related to colorectal cancer and type 2 diabetes mellitus and the drug targets used in the treatment of these diseases. Red nodes represent proteins or drug targets related to colorectal cancer, blue nodes represent those related to type 2 diabetes, while purple nodes represent those related to both. Ellipses, octagons and squares represent proteins related to diseases, drug targets without known side effects and drug targets with known side effects, respectively. Node highlighted by green box (a.) is the TCF7L2 protein related to both diseases, which is the transcription factor 7-like 2 participating in the Wnt signalling pathway and modulating MYC expression. The highly interconnected node cluster highlighted by green box (b.) contains 11 drug targets without known side effects used in the treatment of colorectal cancer, which are all tubuline chain proteins. Node highlighted by green box (c.) representing protein GLP1R, the glucagon-like peptide 1 receptor, is connected only to node TUBB3 of the tubuline cluster (b.). The highly interconnected node cluster highlighted by green box (d.) contains 5 drug targets with known side effects used in the treatment of type 2 diabetes which are the peroxisome proliferator-activated receptors alpha (PPARA), gamma (PPARG) and delta (PPARD) and the estrogen-related receptors alpha (ESRRA) and gamma (ESSRG). The network hub highlighted by green box (e.) is TP53, the cellular tumour antigen p53. Node sizes are proportional to the degrees of the respective proteins in the full human protein-protein interaction network. All proteins here are referenced by their UniProt ID 9 . The human interactome containing 12,439 proteins and 174,666 edges was built from the STRING database 1 , 1,726 human drug targets were obtained from the DrugBank database 2 and 99,423 drug-side effect pairs were taken from the SIDER database 3 . Node degrees were calculated with the Pajek programme 6 as described in the Methods section of the main text. The figure was created using Cytoscape Tables   Table 1│Drugs obtained , and their side effects were collected from the SIDER database 3 . Table 2│The "diabetes mellitus" Anti-diabetes 36
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DB00176 Fluvoxamine
DB00177 Valsartan
DB00178 Ramipril
DB00180 Flunisolide
DB00182 Amphetamine
DB00184 Nicotine
DB00185 Cevimeline
DB00186 Lorazepam
DB00187 Esmolol
DB00188 Bortezomib
DB00191 Phentermine
DB00193 Tramadol
DB00195 Betaxolol
DB00197 Troglitazone
DB00198 Oseltamivir
DB00200 Hydroxocobalamin
DB00201 Caffeine
DB00202 Succinylcholine
DB00204 Dofetilide
DB00205 Pyrimethamine
DB00206 Reserpine
DB00208 Ticlopidine
DBID Drug Name
DB00210 Adapalene
DB00211 Midodrine
DB00213 Pantoprazole
DB00214 Torasemide
DB00215 Citalopram
DB00216 Eletriptan
DB00218 Moxifloxacin
DB00222 Glimepiride
DB00227 Lovastatin
DB00228 Enflurane
DB00231 Temazepam
DB00240 Alclometasone
DB00242 Cladribine
DB00243 Ranolazine
DB00246 Ziprasidone
DB00247 Methysergide
DB00248 Cabergoline
DB00252 Phenytoin
DB00253 Medrysone
DB00257 Clotrimazole
DB00264 Metoprolol
DB00268 Ropinirole
DB00273 Topiramate
DB00276 Amsacrine
DB00277 Theophylline
DB00278 Argatroban
DB00280 Disopyramide
DB00281 Lidocaine
DB00282 Pamidronate
DB00284 Acarbose
DB00285 Venlafaxine
DB00286 Conjugated Estrogens
DB00287 Travoprost
DB00288 Amcinonide
DBID Drug Name
DB00289 Atomoxetine
DB00292 Etomidate
DB00293 Raltitrexed
DB00295 Morphine
DB00296 Ropivacaine
DB00297 Bupivacaine
DB00302 Tranexamic Acid
DB00307 Bexarotene
DB00308 Ibutilide
DB00310 Chlorthalidone
DB00312 Pentobarbital
DB00313 Valproic Acid
DB00315 Zolmitriptan
DB00316 Acetaminophen
DB00317 Gefitinib
DB00318 Codeine
DB00320 Dihydroergotamine
DB00321 Amitriptyline
DB00323 Tolcapone
DB00324 Fluorometholone
DB00327 Hydromorphone
DB00328 Indomethacin
DB00331 Metformin
DB00332 Ipratropium bromide
DB00333 Methadone
DB00334 Olanzapine
DB00335 Atenolol
DB00337 Pimecrolimus
DB00338 Omeprazole
DB00343 Diltiazem
DB00344 Protriptyline
DB00346 Alfuzosin
DB00349 Clobazam
DB00350 Minoxidil
DBID Drug Name
DB00351 Megestrol
DB00356 Chlorzoxazone
DB00357 Aminoglutethimide
DB00358 Mefloquine
DB00360 Tetrahydrobiopterin
DB00361 Vinorelbine
DB00363 Clozapine
DB00364 Sucralfate
DB00367 Levonorgestrel
DB00368 Norepinephrine
DB00370 Mirtazapine
DB00371 Meprobamate
DB00373 Timolol
DB00374 Treprostinil
DB00376 Trihexyphenidyl
DB00377 Palonosetron
DB00379 Mexiletine
DB00380 Dexrazoxane
DB00381 Amlodipine
DB00382 Tacrine
DB00384 Triamterene
DB00388 Phenylephrine
DB00390 Digoxin
DB00393 Nimodipine
DB00396 Progesterone
DB00398 Sorafenib
DB00401 Nisoldipine
DB00404 Alprazolam
DB00408 Loxapine
DB00411 Carbachol
DB00412 Rosiglitazone
DB00413 Pramipexole
DB00418 Secobarbital
DB00419 Miglustat
DB00421 Spironolactone
DB00422 Methylphenidate
DB00423 Methocarbamol
DB00425 Zolpidem
DBID Drug Name
DB00431 Lindane
DB00433 Prochlorperazine
DB00434 Cyproheptadine
DB00437 Allopurinol
DB00439 Cerivastatin
DB00440 Trimethoprim
DB00441 Gemcitabine
DB00444 Teniposide
DB00446 Chloramphenicol
DB00448 Lansoprazole
DB00449 Dipivefrin
DB00450 Droperidol
DB00454 Meperidine
DB00457 Prazosin
DB00458 Imipramine
DB00459 Acitretin
DB00461 Nabumetone
DB00462 Methylscopolamine
DB00465 Ketorolac
DB00471 Montelukast
DB00472 Fluoxetine
DB00474 Methohexital
DB00475 Chlordiazepoxide
DB00476 Duloxetine
DB00477 Chlorpromazine
DB00480 Lenalidomide
DB00481 Raloxifene
DB00482 Celecoxib
DB00484 Brimonidine
DB00486 Nabilone
DB00489 Sotalol
DB00490 Buspirone
DB00491 Miglitol
DB00492 Fosinopril
DB00494 Entacapone
DB00496 Darifenacin
DB00497 Oxycodone
DB00499 Flutamide
DBID Drug Name
DB00500 Tolmetin
DB00501 Cimetidine
DB00502 Haloperidol
DB00518 Albendazole
DB00519 Trandolapril
DB00521 Carteolol
DB00530 Erlotinib
DB00532 Mephenytoin
DB00533 Rofecoxib
DB00535 Cefdinir
DB00537 Ciprofloxacin
DB00539 Toremifene
DB00540 Nortriptyline
DB00541 Vincristine
DB00542 Benazepril
DB00543 Amoxapine
DB00545 Pyridostigmine
DB00547 Desoximetasone
DB00548 Azelaic Acid
DB00549 Zafirlukast
DB00550 Propylthiouracil
DB00554 Piroxicam
DB00555 Lamotrigine
DB00558 Zanamivir
DB00559 Bosentan
DB00561 Doxapram
DB00563 Methotrexate
DB00564 Carbamazepine
DB00571 Propranolol
DB00572 Atropine
DB00573 Fenoprofen
DB00575 Clonidine
DB00580 Valdecoxib
DB00585 Nizatidine
DB00586 Diclofenac
DB00590 Doxazosin
DB00591 Fluocinolone Acetonide
DB00593 Ethosuximide
DBID Drug Name
DB00594 Amiloride
DB00598 Labetalol
DB00602 Ivermectin
DB00603 Medroxyprogesterone
DB00605 Sulindac
DB00608 Chloroquine
DB00611 Butorphanol
DB00612 Bisoprolol
DB00615 Rifabutin
DB00619 Imatinib
DB00620 Triamcinolone
DB00621 Oxandrolone
DB00622 Nicardipine
DB00623 Fluphenazine
DB00624 Testosterone
DB00630 Alendronate
DB00631 Clofarabine
DB00633 Dexmedetomidine
DB00635 Prednisone
DB00640 Adenosine
DB00641 Simvastatin
DB00642 Pemetrexed
DB00647 Propoxyphene
DB00650 Leucovorin
DB00651 Dyphylline
DB00652 Pentazocine
DB00654 Latanoprost
DB00656 Trazodone
DB00659 Acamprosate
DB00661 Verapamil
DB00665 Nilutamide
DB00668 Epinephrine
DB00669 Sumatriptan
DB00672 Chlorpropamide
DB00673 Aprepitant
DB00674 Galantamine
DB00675 Tamoxifen
DB00678 Losartan
DBID Drug Name
DB00679 Thioridazine
DB00680 Moricizine
DB00683 Midazolam
DB00685 Trovafloxacin
DB00687 Fludrocortisone
DB00690 Flurazepam
DB00691 Moexipril
DB00692 Phentolamine
DB00694 Daunorubicin
DB00695 Furosemide
DB00696 Ergotamine
DB00697 Tizanidine
DB00700 Eplerenone
DB00703 Methazolamide
DB00704 Naltrexone
DB00706 Tamsulosin
DB00708 Sufentanil
DB00710 Ibandronate
DB00712 Flurbiprofen
DB00714 Apomorphine
DB00715 Paroxetine
DB00720 Clodronate
DB00721 Procaine
DB00724 Imiquimod
DB00727 Nitroglycerin
DB00728 Rocuronium
DB00731 Nateglinide
DB00733 Pralidoxime
DB00734 Risperidone
DB00735 Naftifine
DB00740 Riluzole
DB00745 Modafinil
DB00747 Scopolamine
DB00749 Etodolac
DB00750 Prilocaine
DB00751 Epinastine
DB00753 Isoflurane
DB00754 Ethotoin
DBID Drug Name
DB00757 Dolasetron
DB00758 Clopidogrel
DB00762 Irinotecan
DB00763 Methimazole
DB00764 Mometasone
DB00768 Olopatadine
DB00772 Malathion
DB00773 Etoposide
DB00774 Hydroflumethiazide
DB00775 Tirofiban
DB00776 Oxcarbazepine
DB00780 Phenelzine
DB00782 Propantheline
DB00783 Estradiol
DB00784 Mefenamic acid
DB00788 Naproxen
DB00790 Perindopril
DB00794 Primidone
DB00795 Sulfasalazine
DB00796 Candesartan
DB00798 Gentamicin
DB00799 Tazarotene
DB00800 Fenoldopam
DB00802 Alfentanil
DB00804 Dicyclomine
DB00806 Pentoxifylline
DB00807 Proparacaine
DB00808 Indapamide
DB00809 Tropicamide
DB00810 Biperiden
DB00811 Ribavirin
DB00813 Fentanyl
DB00814 Meloxicam
DB00818 Propofol
DB00819 Acetazolamide
DB00822 Disulfiram
DB00829 Diazepam
DB00831 Trifluoperazine
DBID Drug Name
DB00834 Mifepristone
DB00835 Brompheniramine
DB00836 Loperamide
DB00838 Clocortolone
DB00839 Tolazamide
DB00841 Dobutamine
DB00842 Oxazepam
DB00843 Donepezil
DB00844 Nalbuphine
DB00850 Perphenazine
DB00851 Dacarbazine
DB00857 Terbinafine
DB00860 Prednisolone
DB00861 Diflunisal
DB00863 Ranitidine
DB00864 Tacrolimus
DB00868 Benzonatate
DB00869 Dorzolamide
DB00870 Suprofen
DB00871 Terbutaline
DB00872 Conivaptan
DB00873 Loteprednol
DB00876 Eprosartan
DB00881 Quinapril
DB00883 Isosorbide Dinitrate
DB00884 Risedronate
DB00887 Bumetanide
DB00889 Granisetron
DB00896 Rimexolone
DB00897 Triazolam
DB00898 Ethanol
DB00899 Remifentanil
DB00900 Didanosine
DB00903 Ethacrynic acid
DB00904 Ondansetron
DB00905 Bimatoprost
DB00906 Tiagabine
DB00907 Cocaine
DBID Drug Name
DB00908 Quinidine
DB00909 Zonisamide
DB00910 Paricalcitol
DB00912 Repaglinide
DB00915 Amantadine
DB00918 Almotriptan
DB00920 Ketotifen
DB00921 Buprenorphine
DB00924 Cyclobenzaprine
DB00925 Phenoxybenzamine
DB00927 Famotidine
DB00929 Misoprostol
DB00933 Mesoridazine
DB00937 Diethylpropion
DB00938 Salmeterol
DB00949 Felbamate
DB00952 Naratriptan
DB00953 Rizatriptan
DB00959 Methylprednisolone
DB00960 Pindolol
DB00961 Mepivacaine
DB00962 Zaleplon
DB00963 Bromfenac
DB00964 Apraclonidine
DB00966 Telmisartan
DB00968 Methyldopa
DB00969 Alosetron
DB00973 Ezetimibe
DB00975 Dipyridamole
DB00978 Lomefloxacin
DB00979 Cyclopentolate
DB00980 Ramelteon
DB00981 Physostigmine
DB00983 Formoterol
DB00986 Glycopyrrolate
DB00988 Dopamine
DB00989 Rivastigmine
DB00990 Exemestane
DBID Drug Name
DB00991 Oxaprozin
DB00992 Methyl aminolevulinate
DB00993 Azathioprine
DB00996 Gabapentin
DB00997 Doxorubicin
DB00998 Frovatriptan
DB00999 Hydrochlorothiazide
DB01001 Salbutamol
DB01005 Hydroxyurea
DB01006 Letrozole
DB01009 Ketoprofen
DB01012 Cinacalcet
DB01013 Clobetasol
DB01014 Balsalazide
DB01017 Minocycline
DB01018 Guanfacine
DB01019 Bethanechol
DB01023 Felodipine
DB01024 Mycophenolic acid
DB01029 Irbesartan
DB01030 Topotecan
DB01032 Probenecid
DB01035 Procainamide
DB01036 Tolterodine
DB01037 Selegiline
DB01039 Fenofibrate
DB01041 Thalidomide
DB01043 Memantine
DB01047 Fluocinonide
DB01050 Ibuprofen
DB01057 Echothiophate
DB01059 Norfloxacin
DB01062 Oxybutynin
DB01064 Isoproterenol
DB01067 Glipizide
DB01068 Clonazepam
DB01069 Promethazine
DB01073 Fludarabine
DBID Drug Name
DB01076 Atorvastatin
DB01079 Tegaserod
DB01083 Orlistat
DB01085 Pilocarpine
DB01086 Benzocaine
DB01087 Primaquine
DB01088 Iloprost
DB01091 Butenafine
DB01095 Fluvastatin
DB01097 Leflunomide
DB01098 Rosuvastatin
DB01100 Pimozide
DB01101 Capecitabine
DB01104 Sertraline
DB01105 Sibutramine
DB01106 Levocabastine
DB01109 Heparin
DB01110 Miconazole
DB01114 Chlorpheniramine
DB01115 Nifedipine
DB01118 Amiodarone
DB01119 Diazoxide
DB01120 Gliclazide
DB01122 Ambenonium
DB01126 Dutasteride
DB01128 Bicalutamide
DB01129 Rabeprazole
DB01130 Prednicarbate
DB01132 Pioglitazone
DB01133 Tiludronate
DB01136 Carvedilol
DB01142 Doxepin
DB01143 Amifostine
DB01148 Flavoxate
DB01149 Nefazodone
DB01151 Desipramine
DB01156 Bupropion
DB01157 Trimetrexate
DBID Drug Name
DB01158 Bretylium
DB01159 Halothane
DB01161 Chloroprocaine
DB01162 Terazosin
DB01165 Ofloxacin
DB01167 Itraconazole
DB01169 Arsenic trioxide
DB01173 Orphenadrine
DB01174 Phenobarbital
DB01177 Idarubicin
DB01182 Propafenone
DB01183 Naloxone
DB01184 Domperidone
DB01185 Fluoxymesterone
DB01186 Pergolide
DB01189 Desflurane
DB01193 Acebutolol
DB01194 Brinzolamide
DB01195 Flecainide
DB01196 Estramustine
DB01197 Captopril
DB01198 Zopiclone
DB01200 Bromocriptine
DB01202 Levetiracetam
DB01203 Nadolol
DB01204 Mitoxantrone
DB01205 Flumazenil
DB01206 Lomustine
DB01210 Levobunolol
DB01214 Metipranolol
DB01215 Estazolam
DB01216 Finasteride
DB01217 Anastrozole
DB01218 Halofantrine
DB01219 Dantrolene
DB01220 Rifaximin
DB01221 Ketamine
DB01222 Budesonide
DBID Drug Name
DB01223 Aminophylline
DB01224 Quetiapine
DB01226 Mivacurium
DB01229 Paclitaxel
DB01233 Metoclopramide
DB01234 Dexamethasone
DB01236 Sevoflurane
DB01238 Aripiprazole
DB01241 Gemfibrozil
DB01242 Clomipramine
DB01247 Isocarboxazid
DB01248 Docetaxel
DB01250 Olsalazine
DB01254 Dasatinib
DB01258 Aliskiren
DB01260 Desonide
DB01261 Sitagliptin
DB01267 Paliperidone
DB01268 Sunitinib
DB01273 Varenicline
DB01275 Hydralazine
DB01276 Exenatide
DB01278 Pramlintide
DB01280 Nelarabine
DB01291 Pirbuterol
DB01306 Insulin Aspart
DB01320 Fosphenytoin
DB01327 Cefazolin
DB01337 Pancuronium
DB01340 Cilazapril
DB01356 Lithium
DB01364 Ephedrine
DB01367 Rasagiline
DB01373 Calcium
DB01378 Magnesium
DB01393
The keywords are listed which were used in the filtering of the DrugBank database 2 and their occurrences is noted. The plus sign (+) represents the "AND" logical operator, the slash (/) represents the "OR" logical operator. . Only those drugs were selected, which are used in the treatment of colorectal cancer and have no reported side effects in the SIDER database 3 . Target proteins for each drug were identified by their UniProt ID 9 . , and the proteins were labelled by their UniProt ID 9 . 99,423 drugside effect pairs were taken from the SIDER database 3 . Statistical analysis was performed using the Wilcoxon rank sum (Mann-Whitney) test function of the R package 5 . The table shows the average network distance between drug targets without known side effects used in the treatment of colorectal cancer and colorectal cancer-related proteins. The total number of drug targets without known side effects used in the treatment of colorectal cancer was 24; the total number of colorectal cancer-related proteins was 18. Average network distances were calculated as shortest paths using the Pajek programme 6 . Proteins were labelled by their UniProt ID 9 . The human interactome containing 12,439 proteins and 174,666 edges was built from the STRING database 1 , 1,726 human drug targets were obtained from the DrugBank database 2 and 99,423 drug-side effect pairs were taken from the SIDER database 3 . Colorectal cancer-related proteins were obtained from the Cancer Gene Census database 10 . Average network distances between colorectal cancer-related proteins and at least 50 randomly selected samples of 24 proteins each were calculated, and the statistical difference in their mean values compared to the average network distance of the 24 drug targets listed above was tested using the one-way ANOVA (Analysis of Variance) with linear model fit function of the R package 5 . There was no statistically significant difference between the mean values of the drug targets without known side effects and the random samples, F=0.8807, p=0.7078. Mean network distance of randomly selected proteins 3.240
The table shows the average network distance between drug targets with known side effects used in the treatment of colorectal cancer and colorectal cancer-related proteins. The total number of drug targets with known side effects used in the treatment of colorectal cancer was 3; the total number of colorectal cancer-related proteins was 18. Average network distances were calculated as shortest paths using the Pajek programme 6 . Proteins were labelled by their UniProt ID 9 . The human interactome containing 12,439 proteins and 174,666 edges was built from the STRING database 1 , 1,726 human drug targets were obtained from the DrugBank database 2 and 99,423 drug-side effect pairs were taken from the SIDER database 3 . Colorectal cancer-related proteins were obtained from the Cancer Gene Census database 10 . Average network distances between colorectal cancer related proteins and at least 50 randomly selected samples of 3 proteins each were calculated, and the statistical difference in their mean values compared to the average network distance of the 3 drug targets listed above was tested using the one-way ANOVA (Analysis of Variance) with linear model fit function of the R package 5 . There was no statistically significant difference between the mean values of the drug targets with known side effects and the random samples, F=1.223, p=0.1951. The table shows the average network distance between drug targets without known side effects used in the treatment of type 2 diabetes and diabetes-related proteins. The total number of drug targets without known side effects used in the treatment of type 2 diabetes was 14; the total number of type 2 diabetes-related proteins contained in the human interactome was 14. Average network distances were calculated as shortest paths using the Pajek programme 6 . Proteins were labelled by their UniProt ID 9 . The human interactome containing 12,439 proteins and 174,666 edges was built from the STRING database 1 , 1,726 human drug targets were obtained from the DrugBank database 2 and 99,423 drug-side effect pairs were taken from the SIDER database 3 . Type 2 diabetes-related proteins were obtained from the article of Parchwani et al. 12 . Average network distances between type-2 diabetes related proteins and at least 50 randomly selected samples of 14 proteins each were calculated, and the statistical difference in their mean values compared to the average network distance of the 14 drug targets listed above was tested using the one-way ANOVA (Analysis of Variance) with linear model fit function of the R package 5 . There was no statistically significant difference between the mean values of the drug targets without known side effects and the random samples, F=0.7867, p=0.8547. The table shows the average network distance between drug targets with known side effects used in the treatment of type 2 diabetes and diabetes-related proteins. The total number of drug targets with known side effects used in the treatment of type 2 diabetes was 25; the total number of type 2 diabetes-related proteins contained in the human interactome was 14. Average network distances were calculated as shortest paths using the Pajek programme 6 . Proteins were labelled by their UniProt ID 9 . The human interactome containing 12,439 proteins and 174,666 edges was built from the STRING database 1 , 1,726 human drug targets were obtained from the DrugBank database 2 and 99,423 drug-side effect pairs were taken from the SIDER database 3 . Type 2 diabetes-related proteins were obtained from the article of Parchwani et al. 12 . Average network distances between type-2 diabetes related proteins and at least 50 randomly selected samples of 25 proteins each were calculated, and the statistical difference in their mean values compared to the average network distance of the 25 drug targets listed above was tested using the one-way ANOVA (Analysis of Variance) with linear model fit function of the R package 5 . There was no statistically significant difference between the mean values of the drug targets with known side effects and the random samples, F= 0.9021, p= 0.6677.
